Skip to main content

Table 5 Appropriateness of antibiotic prescription for targeted therapy of meningitis IPD

From: Antibiotics prescription for targeted therapy of pediatric invasive pneumococcal diseases in China: a multicenter retrospective study

Definitive antibiotics therapy

All patients

n = 314

Spn susceptible to penicillin

n = 84

Spn not susceptible to penicillin

n = 230

p

   

Susceptible to cefotaxime

n = 95

Not susceptible to cefotaxime

n = 135

Subtotal

n = 230

 

Penicillins monotherapy

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

–

Cephalosporin monotherapy

39 (12.4)

19 (22.6)

18 (18.9)

2 (1.5)

20 (8.7)

0.001

Carbapenem monotherapy

15 (4.8)

9 (10.7)

6 (6.3)

0 (0)

6 (2.6)

0.007

Cephalosporin plus vancomycin

88 (28.0)

18 (21.4)

26 (27.4)

44 (32.6)

70 (30.4)

0.116

Carbapenem plus vancomycin

94(29.9)

21 (25.0)

26 (27.4)

47 (34.8)

73 (31.7)

0.248

Cephalosporin plus linezolid

26 (8.3)

5 (6.0)

8 (8.4)

13 (9.6)

21 (9.1)

0.366

Carbapenem plus linezolid

21 (6.7)

5 (6.0)

7 (7.4)

9 (6.7)

16 (7.0)

0.753

Vancomycin plus rifampin

16 (5.1)

5 (6.0)

2 (2.1)

9 (6.7)

11 (4.8)

0.899

Vancomycin monotherapy

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

–

Linezolid monotherapy

6 (1.9)

2 (2.4)

1 (1.1)

3 (2.2)

4 (1.7)

1.000

Other prescriptions

9 (2.9)

0 (0)

1a (1.1)

8b (5.9)

9 (3.9)

–

Inappropriate use of

      

 Carbapenems

133 (42.4)

35 (41.7)

40 (42.1)

58 (43.0)

98 (42.6)

0.881

 Vancomycin

109 (34.7)

54 (64.3)

55 (57.9)

0 (0)

55 (23.9)

0.000

 Linezolid

28 (8.9)

12 (14.3)

16 (16.8)

0 (0)

16 (7.0)

0.044

No. patients with inappropriate antibiotic use

200 (63.7)

65 (77.4)

77 (81.1)

58 (43.0)

135 (58.7)

0.002

  1. Spn, Streptococcus pneumoniae
  2. aCarbapenem plus vancomycin and rifampin
  3. b2 patients with cephalosporin plus vancomycin and rifampin, 2 patients with cephalosporin plus linezolid and rifampin, 2 patients with linezolid plus rifampin, 1 patient with carbapenem plus vancomycin and rifampin and 1 patient with carbapenem plus linezolid and rifampin,